Imperial College London
Alternate

Professor Neil Ferguson

Faculty of Medicine, School of Public Health

Director of the School of Public Health
 
 
 
//

Contact

 

+44 (0)20 7594 3296neil.ferguson Website

 
 
//

Location

 

508School of Public HealthWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Miglianico:2018:10.1073/pnas.1801338115,
author = {Miglianico, M and Eldering, M and Slater, H and Ferguson, N and Ambrose, P and Lees, RS and Koolen, KMJ and Pruzinova, K and Jancarova, M and Volf, P and Koenraadt, CJM and Duerr, H-P and Trevitt, G and Yang, B and Chatterjee, AK and Wisler, J and Sturm, A and Bousema, T and Sauerwein, RW and Schultz, PG and Tremblay, MS and Dechering, KJ},
doi = {10.1073/pnas.1801338115},
journal = {Proceedings of the National Academy of Sciences},
pages = {E6920--E6926},
title = {Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases.},
url = {http://dx.doi.org/10.1073/pnas.1801338115},
volume = {115},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Isoxazolines are oral insecticidal drugs currently licensed for ectoparasite control in companion animals. Here we propose their use in humans for the reduction of vector-borne disease incidence. Fluralaner and afoxolaner rapidly killed Anopheles, Aedes, and Culex mosquitoes and Phlebotomus sand flies after feeding on a drug-supplemented blood meal, with IC50 values ranging from 33 to 575 nM, and were fully active against strains with preexisting resistance to common insecticides. Based on allometric scaling of preclinical pharmacokinetics data, we predict that a single human median dose of 260 mg (IQR, 177-407 mg) for afoxolaner, or 410 mg (IQR, 278-648 mg) for fluralaner, could provide an insecticidal effect lasting 50-90 days against mosquitoes and Phlebotomus sand flies. Computational modeling showed that seasonal mass drug administration of such a single dose to a fraction of a regional population would dramatically reduce clinical cases of Zika and malaria in endemic settings. Isoxazolines therefore represent a promising new component of drug-based vector control.
AU  - Miglianico,M
AU  - Eldering,M
AU  - Slater,H
AU  - Ferguson,N
AU  - Ambrose,P
AU  - Lees,RS
AU  - Koolen,KMJ
AU  - Pruzinova,K
AU  - Jancarova,M
AU  - Volf,P
AU  - Koenraadt,CJM
AU  - Duerr,H-P
AU  - Trevitt,G
AU  - Yang,B
AU  - Chatterjee,AK
AU  - Wisler,J
AU  - Sturm,A
AU  - Bousema,T
AU  - Sauerwein,RW
AU  - Schultz,PG
AU  - Tremblay,MS
AU  - Dechering,KJ
DO  - 10.1073/pnas.1801338115
EP  - 6926
PY  - 2018///
SN  - 0027-8424
SP  - 6920
TI  - Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases.
T2  - Proceedings of the National Academy of Sciences
UR  - http://dx.doi.org/10.1073/pnas.1801338115
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29967151
UR  - http://hdl.handle.net/10044/1/61548
VL  - 115
ER  -
Download